RecruitingPhase 2NCT06527300
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Sponsor
Zhejiang Wenda Pharma Technology LTD.
Enrollment
48 participants
Start Date
Apr 25, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.
Eligibility
Min Age: 12 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called NHWD-870 HCl for people with advanced solid tumor (phase 1). The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNHWD-870 HCl
Administered P.O.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06527300
Related Trials
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
NCT0716332511 locations
An Initial Evaluation of AN8025 in Solid Tumors
NCT076390471 location
A Phase I Study of JLM019 Injection
NCT076238501 location
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT071234153 locations